Molly Mahowald is a technology & IP transactions associate in the New York office of Kirkland & Ellis LLP.
Experience
Representative Matters
Scorpion Therapeutics in its $2.5 billion pending sale of the PI3Kα inhibitor program, a treatment for breast cancers in clinical trials, to Eli Lilly and Company (NYSE: LLY).
More
Credentials
Admissions & Qualifications
2025New York
Education
University of Texas at Austin School of LawJ.D.2024
Managing Editor, Texas Intellectual Property Law Journal
